The US nicotine pouch shelf is expanding: who wins the extra 11.3%?
Short answer: US retailers expect to give nicotine pouches 11.3% more shelf space. That does not mean every brand gains space. ZYN leads, VELO is growing, on! has authorized products, and challengers must both secure FDA marketing orders and prove retail velocity.

What 11.3% actually means
Goldman Sachs' Q3 survey of retailers and wholesalers representing roughly 40,000 US stores identifies nicotine pouches as the nicotine category expected to receive the largest shelf-space increase: 11.3% (Convenience Store News). It is an expectation from a large industry sample, not a physical census of every US backbar.
Shelf space is scarce
Retail decisions depend on sales per position, gross profit, supply reliability, trade support and regulatory risk. NACS reports that other tobacco products generated more monthly gross profit per convenience store than cigarettes for the first time in 2025, accounting for 6.7% versus 6.6% of inside-store gross profit (NACS Magazine).
NACS also reports that 87% of modern oral nicotine consumers use multiple nicotine products. Growth is therefore not only a clean substitution away from cigarettes; categories can be purchased in parallel.
Three authorized portfolios
| Portfolio | FDA-listed products | Retail question |
|---|---|---|
| ZYN/ZYN ULTRA | 31 | Can the leader defend facings as formats multiply? |
| VELO Mini | 24 | Can 4mg Mini turn authorization into distribution? |
| on!/on! PLUS | 12 | Can the range regain category space? |
FDA's current list contains 67 products from these three manufacturers (FDA). The 24 VELO entries cover eight product names in three package types, all at 4mg (FDA). List entries are therefore not the same as flavour-strength combinations on shelf.
What this means for challengers
CLEW, FRE, ALP, Rogue and others may have distribution or demand but do not appear on FDA's authorized nicotine-pouch list. A pending PMTA is not a marketing order. See our updated PMTA, MGO and MRTP guide and analysis of JT's CLEW acquisition.
Our assessment
More category space initially favours brands that already combine legal status, strong velocity and reliable supply. FDA authorization can open the door, but it guarantees no facing. The next competitive phase is less about simply “being in the US” and more about measurable store economics.
Four metrics to track
- Sales and gross profit per facing per week.
- Numeric versus weighted distribution.
- Out-of-stock rate and distributor service level.
- Share of stores where authorized SKUs are actually on shelf.
Sources
Need to assess a market, product or regulatory risk?
Book an initial call